PAVmed Inc. – Consensus Indicates Potential 187.0% Upside

Broker Ratings

PAVmed Inc. found using ticker (PAVM) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 5.25 and 5 calculating the mean target price we have 5.08. Given that the stocks previous close was at 1.77 this indicates there is a potential upside of 187.0%. There is a 50 day moving average of 1.87 while the 200 day moving average is 1.97. The company has a market capitalisation of $95m. Find out more information at: http://www.pavmed.com

PAVmed Inc. operates as a medical device company in the United States. The company’s lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index